The results showed that ensartinib was effective and well tolerated in patients with ALK positive non-small cell lung cancer

Among lung cancer, non-small cell lung cancer is the most common type, accounting for 85-90% of all lung cancer, and about 3-8% of NSCLC patients have ALK mutation ALK (anaplastic lymphoma kinase) is a receptor tyrosine kinase, which is highly expressed in a variety of tumor cells, so it becomes a key target of cancer treatment In March this year, a phase I / II study reported by horn of Vanderbilt Ingram cancer center in the United States showed that ensartinib was effective and well tolerated in patients with anaplastic lymphoma kinase (ALK) - positive non-small cell lung cancer (NSCLC) About ensortinib (x-396), ensortinib is a new generation of ALK inhibitors for lung cancer jointly developed by Beida pharmaceutical and xccovery company (http:// which is intended to be used in the first-line and second-line treatment of ALK positive non-small cell lung cancer patients Ensortinib has the activity of anti ALK, and can also target met, ABL, Axl, EphA2, LTK, ros1 and SLK According to the data of phase I / II study released at the 2016 ESMO Conference (http:// most of the non-small cell lung cancer patients who have not used clozatinib are effective in the treatment of ensortinib Ensortinib is also effective in the treatment of patients with clozatinib resistance The proportion of brain metastasis in ALK positive patients is very high, and ensartinib can also effectively treat CNS metastasis; it can also be used in other second-generation ALK inhibitors (such as ceritinib and alectinib) after treatment Researchers from Vanderbilt Ingram cancer center, a related study, included patients with advanced ALK positive non-small cell lung cancer in this dose escalation study, 37 patients were included in the dose escalation study, and 60 patients were included in the dose escalation study to evaluate the safety of ensortinib and determine its phase II clinical trial (http:// To evaluate the pharmacokinetics and antitumor activity of rp2d in the first phase I / II clinical trial The results showed that the response rate (RR) was 60% and the median progression free survival time (PFS) was 9.2 months in the patients with ALK positive and evaluable effect The RR of the patients with ALK and TKI was 80%, and the median PFS was 26.2 months In the past, 69% of the patients received only clozatinib, and the median PFS was 9.0 months It can bring relief to the central nervous system, and the intracranial RR is 64% Currently, ensortinib is in the process of international multicenter phase III clinical research.